CHH 100: ICI HEMOPHILIA & OTHER RARE BLEEDING DISORDERS PRECEPTORSHIP

Multidisciplinary management, standards of care, optimal diagnostics, therapies, and future perspectives in the care of Hemophilia patients and those with rare bleeding disorders in sub-Saharan Africa.

Eldoret, Kenya

6^th October 2020- 19^th November 2020

Lead Faculty: Prof. Anne Greist MD

Professor of Medicine (Hematologist & Medical Oncologist)-Indiana University. U.S.A

Medical Director-Indiana Hemophilia and Thrombosis Center (IHTC)

Indianapolis, Indiana

Course Director: Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI). P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com Website: www.intercancer.com

This educational activity is provided by the International Cancer Institute (ICI).  This activity is supported by an educational grant from Roche through the ICI_Roche Shining Tower Project.

Faculty

1. Kibet Shikuku- Hematologist
2. Festus Njuguna- Pediatrician (Hematology/ Oncology)
3. TBD-Physiotherapist
4. TBD-Hemophilia Nurse
5. TBD-Hemophilia Pharmacist
6. Guest Faculty-TBC

Accreditation by KMPDC, KPPB, NCK, and COC

Target Audience

The primary target audience for this course comprises the multidisciplinary clinical Hematology and/or hemophilia care team members including, but not limited to physicians; fellows; residents; researchers; HEMOPHILIA nurse practitioners and HEMOPHILIA nurses; HEMOPHILIA pharmacists; HEMOPHILIA PharmTechs; HEMOPHILIA clinical officers; physician assistants; Laboratory scientists and technicians and other allied health care professionals and hemophilia advocates.

Topics covered in this course

At the end of this educational activity, participants will have covered the following topics:

1. Hemophilia A and B

Presentation, pathophysiology, and diagnosis

Treatment of bleeding episodes; hemophilia emergencies

Management of surgery

Inhibitors

Prophylaxis and Novel therapies

2. Von Willebrand disease

Presentation, pathophysiology, diagnosis

Management of VWD;

3. Disorders of platelet number and function
4. Rare coagulation factor deficiencies

Fibrinogen disorders and PAI-1 deficiency

Other rare disorders: II, V, X, XI, XIII

5. Acquired factor deficiencies
6. Bleeding disorders in women and girls

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program LECTURES

Orientation to the course (Chite) Tuesday 6^th October 2020 4:00-4:30 PM EAT

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours)

All those interested in registration to this course, please send your information (quote the course title CHH 100 in the subject line of your email) to education@intercancer.com

Acknowledgments

ICI acknowledges that the funding for this preceptorship training has been proudly supported by the Roche through the ICI_Roche Shining Tower Project.